Psychedelic Inequality.

This article examines the issue of limited access to psychedelic therapies in the United States. It discusses how the high cost of these treatments creates inequality, as wealthy individuals can afford them while lower- and middle-income Americans cannot. The psychedelics industry is also driven by profit, leaving marginalized communities without access to these therapies. The author shares their personal experience and explores potential solutions, such as FDA approval, insurance coverage, and decriminalization. However, the article cautions that these solutions may create new inequalities and highlights the importance of making these therapies accessible to those who could benefit from them. [Extracted from the article]

Copyright of Nation is the property of Nation Company, L. P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)